secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2026-07-22T12:35:29+00:00
Accession:  0001493152-26-034185
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma collaborates with Bayer to test ENV-105 + XOFIGO in mCRPC; market up to $1.3B
--------------------------------------------------------------------------------

- Bayer to supply radium for Kairos' study of ENV-105 (carotuximab) with XOFIGO in metastatic castration-resistant prostate cancer.
- Prior Phase 2 data showed 86% clinical benefit rate and median PFS >13 months in resistant mCRPC.
- Addressable global market estimated at $570M–$1.3B.
- ENV-105 targets CD105 to re-sensitize tumors; XOFIGO is FDA-approved alpha-emitting radiopharmaceutical.
- Collaboration includes customary terms; Kairos responsible for study financing and management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/0001493152-26-034185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-034185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer